Dr. Falk Pharma GmbH Enrolls First Patients into Pivotal Phase III Trial with LT-02

News   Nov 01, 2014

 
Dr. Falk Pharma GmbH Enrolls First Patients into Pivotal Phase III Trial with LT-02
 
 
 

RELATED ARTICLES

Cancer Cells’ Energy Source Blocked by Natural Compound

News

Researchers have not only untangled an unusual wiring system that cancer cells use for carbohydrate metabolism, but also identified a natural compound that appears to selectively shut down this system in laboratory studies.

READ MORE

Trispecific Antibodies Protect Against HIV

News

A three-pronged antibody made in the laboratory protected monkeys from infection with two strains of SHIV, a monkey form of HIV, better than individual natural antibodies from which the engineered antibody is derived.

READ MORE

Drug Discovery Alliance Formed to Help Increase Drug Development Success Rate

News

Two prominent preclinical safety companies have launched a unique European alliance to address the high safety-related failure rate in drug development.

READ MORE

 

Comments | 0 ADD COMMENT

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE